Mr. Joel Shacker reports

CORE ONE ENTERS INTO LOAN AGREEMENT WITH RIGHT SEASON INVESTMENTS

Core One Labs Inc. has entered into a loan agreement with Right Season Investments Corp. dated June 28, 2024. Under the terms of the loan agreement, Right Season has advanced a loan of $300,000 to the company. The loan is repayable upon demand of Right Season and carries an interest rate of 15 per cent per annum, effective from the date of the loan advance until full repayment. The company plans to utilize the loan proceeds for general administrative and working capital expenses.

About Core One Labs Inc.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration of novel delivery systems technology.

The company has a multifaceted business approach, and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders under its 100-per-cent-owned subsidiary Akome Biotech Ltd., and, through its 100-per-cent-owned subsidiary, Awakened Biosciences Inc., Core One has developed a proprietary method for the production of synthetic psilocybin.

We seek Safe Harbor.